Clinical Trials Sponsored by BeiGene, Ltd.

Total 18782 results

Celgene

Completed

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

Small Cell Lung Cancer

United States, Netherlands, United Kingdom
Celgene

Completed

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Multiple Myeloma

Russian Federation
Celgene

Active, not recruiting

A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR

Multiple Myeloma

Turkey
Celgene

Completed

An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (OCEAN)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic
Celgene

Completed

Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response

Healthy Volunteer

United States
Celgene

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Leukemia, Myelomonocytic, Juvenile | Myelodysplastic Syndrome

Spain, Germany, Italy, United Kingdom, Belgium, France, Denmark, Netherlands, Sweden, Switzerland, Austria, Czechia, Ireland
Celgene

Completed

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myelogenous Leukemia

United States, Canada
Celgene

Completed

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Breast Neoplasms | Pancreatic Neoplasms

United States
Celgene

Completed

Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate

Healthy Volunteers

United States
Celgene

Completed

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity)

Breast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...

United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
Celgene

Completed

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Lymphoma, T-cell, Peripheral

Japan
Celgene

Completed

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Heathy Volunteer

United States
Celgene

Completed

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

Healthy Volunteer

United States
Celgene

No longer available

Expanded Access for CC-2001

Other | Dermatologic

United States
Celgene

No longer available

Expanded Access for CC-4047

Multiple Myeloma

United States
Celgene

Completed

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2 (AboundPS2)

Carcinoma, Non-Small-Cell Lung

United States
Celgene

Completed

Radiolabeled Study of AG-221 in Healthy Male Subjects.

Healthy Volunteers
Celgene

Completed

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study (NIMBUS)

Multiple Myeloma

United States, Netherlands, Canada, Belgium, United Kingdom, Australia, Denmark, Germany, Spain, Switzerland, France, Italy, Greece, Russian Federation, Sweden, Czechia
Celgene

Completed

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (ABOUND 70+)

Adenocarcinoma | Carcinoma | Non-Small Cell Lung Cancer | Carcinoma, Large Cell | Squamous Cell Carcinoma | Lung Neoplasm

United States
Celgene

Terminated

Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease

Crohn's Disease

Italy
Celgene

Completed

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Adult T-Cell Leukemia-Lymphoma

Japan
Celgene

Completed

AVIDA The Vidaza® (Azacitidine) Patient Registry (AVIDA)

Myelodysplastic Syndromes

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

Renal Insufficiency

United States
Celgene

Completed

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail)

Prostate Cancer

United States, Spain, France, Belgium, Australia, Denmark, Austria, United Kingdom, Netherlands, Poland, Israel, Italy, Germany, Greece, Canada, Czechia, Hungary, Mexico, Russian Federation, South Africa, Sweden
Celgene

Completed

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

Advanced Cancer

Australia
Celgene

Completed

Radiolabeled Study of CC-220 in Healthy Male Subjects

Healthy Volunteer

United States
Celgene

Completed

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Korea, Republic of, United Kingdom, Australia, Taiwan, Israel, Canada, Spain, China, Italy, Germany, Netherlands, Russian Federation, Belgium, France, Poland, Czechia, Austria
Celgene

Completed

Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Celgene

Completed

A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms

Myelodysplastic Syndromes | Multiple Myeloma | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia Myeloid Acute

Spain
Celgene

Completed

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States, Switzerland, Canada
Celgene

Terminated

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

Carcinoma, Hepatocellular

United States
Celgene

Completed

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin's

United States, Spain, Germany, France, Italy, Canada, United Kingdom
Celgene

Completed

Abraxane in Treatment of Metastatic Breast Cancer

Metastatic Breast Cancer

Austria
Celgene

Completed

A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis

Anemia | Kidney Failure, Chronic

Belgium, Spain, United Kingdom, Portugal, Germany
Celgene

Completed

A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults

Healthy Volunteers

United Kingdom
Celgene

Completed

A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects

Healthy Volunteers

United Kingdom
MediGene

Completed

Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers

Anogenital Warts

Germany
MediGene

Terminated

Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation

Pharmacokinetics

United Kingdom
MediGene

Completed

EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

Adenocarcinoma | Metastasis | Pancreas Neoplasms

Ukraine, Czech Republic, Hungary
MediGene

Completed

Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®

Pharmacokinetics

United Kingdom
MediGene

Completed

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

Condylomata Acuminata

United States, Argentina, Chile, Colombia, Mexico, Peru, Romania
MediGene

Completed

Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer

Glioma | Glioblastoma | Astrocytoma
Peter MacCallum Cancer Centre, Australia
Celgene Corporation; Janssen-Cilag Ltd.

Unknown

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Multiple Myeloma

Australia
Lund University Hospital
Mundipharma Pte Ltd.; Roche Pharma AG; Celgene

Completed

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. (LENA-BERIT)

Mantle Cell Lymphoma

Finland, Denmark, Norway, Sweden
Qilu Hospital of Shandong University
BeiGene

Recruiting

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Sun Yat-sen University
Hutchmed; BeiGene

Not yet recruiting

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Metastatic Colorectal Cancer | mCRC

China
Shandong Cancer Hospital and Institute
BeiGene

Active, not recruiting

A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma (Notable-HCC)

Hepatocellular Carcinoma

China
PETHEMA Foundation
Celgene; Janssen-Cilag Ltd.; TFS Trial Form Support

Completed

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Multiple Myeloma

Spain
Zhonglin Hao
University of Kentucky; BeiGene

Withdrawn

ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer (CRATER)

Esophageal Cancer | Esophagogastric Junction Cancer

United States

3

Subscribe